Skip to content
Screener

Xeris Biopharma Holdings, Inc. XERS Q4 2025 Annual earnings

Reported March 2, 2026 · Before market open

Revenue$85.8MBeat by $3.6M
EPS$0.06Beat by $0.03
Revenue estimate$82.2M
EPS estimate$0.03

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$101.6M
EPS estimate$0.02

Financials

Q4 2025

Income statement

See full
Revenue$85.8M+42.8%
Gross profit$74.9M+47.9%
Operating income$16.8M—
Net income$11.1M+317%
EPS (diluted)$0.07+333%

Balance sheet

See full
Cash & equivalents$111.0M+55.0%
Total debt$258.1M-4.9%
Total equity$13.7M+146%
Total assets$383.5M+18.7%

Cash flow

See full
Operating cash flow$20.0M—

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.3B+158%
Enterprise value$1.45B+106%
P/E2,351.1×—
P/S4.5×+2.0×

Profitability

See full
Gross margin85.4%+3.6pp
Operating margin8.5%+5.1pp
Net margin0.2%+0.1pp

Returns & leverage

See full
Debt / equity18.9×—
Current ratio2.2×+0.5×

Segments

By product

See full
Recorlev$45.3M+100%
Gvoke$24.6M+5.9%
Keveyis$12.8M+15.1%
Royalty, contract and other revenue$2.4M-23.3%
Other product revenue$651.0K—

FAQ

When did Xeris Biopharma Holdings, Inc. report Q4 2025 earnings?
Xeris Biopharma Holdings, Inc. (XERS) reported Q4 2025 earnings on March 2, 2026 before market open.
What were Xeris Biopharma Holdings, Inc.'s Q4 2025 revenue and EPS?
Xeris Biopharma Holdings, Inc. reported revenue of $85.8M and eps of $0.06 for Q4 2025.
Did Xeris Biopharma Holdings, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $82.2M by $3.6M. EPS beat the consensus estimate of $0.03 by $0.03.
How did Xeris Biopharma Holdings, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 42.8% from $60.1M a year earlier.
Where can I find Xeris Biopharma Holdings, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001867096-26-000010) and the 10-K periodic report (0001867096-26-000016) directly on SEC EDGAR. The filing index links above go to sec.gov.